Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 12Completed 6Unknown 4Terminated 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1Genetic Diseases, Inborn 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Clinical Trials, Phase II as Topic × Clear all
NCT03683277 2025-02-19

IFM2014-01

Intergroupe Francophone du Myelome

Phase 2 Terminated
26 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Genetic Diseases, Inborn

NCT02382406 2023-05-23

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Hoosier Cancer Research Network

Phase 1/2 Terminated
46 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡